Efficacy of Proprietary Cherry Juice Blend in Osteoarthritis of the Knee
NCT ID: NCT00443092
Last Updated: 2012-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
59 participants
INTERVENTIONAL
2007-03-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a prospective double blind, placebo controlled cross-over study.
The study will be performed in the Philadelphia VA Medical Center 1 South Rheumatology Clinic with patients meeting ACR criteria for Kellgren grade 2-3 knee osteoarthritis and 4-9 pain severity on a VAS. Fifty patients will be studied with each having 5 visits. Subjects will take either the proprietary cherry blend or placebo for 6 weeks and then switch. WOMAC pain and function will be the primary outcome with acetaminophen use, walking time and serum uric acid as secondary outcomes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
proprietary tart cherry juice blend (8 oz., BID)
proprietary cherry juice blend (food)
2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
2
control juice (color matched kool aid blend),(8 oz., BID)
control juice (kool aid blend)
2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
proprietary cherry juice blend (food)
2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
control juice (kool aid blend)
2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is over 18 years and less than 80 years
* Subject has mild to moderate osteoarthritis of the knee based on all of the following 3:
1. Meets clinical ACR criteria
2. Kellgren score of 2-3 on a Standing Knee x-ray within previous 24 months
3. VAS pain score of 4-9 at screening visit
Exclusion Criteria
* Chronic pain syndrome (fibromyalgia)
* Corticosteroid medication in last 2 months, either intra-articular or oral
* Intra-articular injections of hyaluronic acid in last 9 months
* Pregnant women (weight gain might confound degree of knee pain)
* Diabetes
* Inability to discontinue prescription medication for arthritis
* Unstable medical conditions that would likely prevent the subject from completing the study
* Food allergies - cherries, apples
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CherryPharm
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cherry Pharm
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
H. R Schumacher, M.D.
Role: PRINCIPAL_INVESTIGATOR
VA Medical Center, Philadelphia & University of Pennsylvania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Medical Center
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
BLAU LW. Cherry diet control for gout and arthritis. Tex Rep Biol Med. 1950;8(3):309-11. No abstract available.
Connolly DA, McHugh MP, Padilla-Zakour OI, Carlson L, Sayers SP. Efficacy of a tart cherry juice blend in preventing the symptoms of muscle damage. Br J Sports Med. 2006 Aug;40(8):679-83; discussion 683. doi: 10.1136/bjsm.2005.025429. Epub 2006 Jun 21.
Seeram NP, Momin RA, Nair MG, Bourquin LD. Cyclooxygenase inhibitory and antioxidant cyanidin glycosides in cherries and berries. Phytomedicine. 2001 Sep;8(5):362-9. doi: 10.1078/0944-7113-00053.
He YH, Zhou J, Wang YS, Xiao C, Tong Y, Tang JC, Chan AS, Lu AP. Anti-inflammatory and anti-oxidative effects of cherries on Freund's adjuvant-induced arthritis in rats. Scand J Rheumatol. 2006 Sep-Oct;35(5):356-8. doi: 10.1080/03009740600704155.
Jacob RA, Spinozzi GM, Simon VA, Kelley DS, Prior RL, Hess-Pierce B, Kader AA. Consumption of cherries lowers plasma urate in healthy women. J Nutr. 2003 Jun;133(6):1826-9. doi: 10.1093/jn/133.6.1826.
Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R, Wolfe F, Gibofsky A, Simon L, Zlotnick S, Fort JG. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004 Aug;63(8):931-9. doi: 10.1136/ard.2003.020313. Epub 2004 Apr 13.
Johanson NA, Liang MH, Daltroy L, Rudicel S, Richmond J. American Academy of Orthopaedic Surgeons lower limb outcomes assessment instruments. Reliability, validity, and sensitivity to change. J Bone Joint Surg Am. 2004 May;86(5):902-9. doi: 10.2106/00004623-200405000-00003.
Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986 Aug;29(8):1039-49. doi: 10.1002/art.1780290816.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VA MIRB ID # 00981
Identifier Type: -
Identifier Source: secondary_id
CP100M
Identifier Type: -
Identifier Source: org_study_id